Orthocell Ltd. (OCC.AX), a regenerative medicine company announced that it has approval for its Remplir nerve repair device to be used across the 51 United States Department of Defence and 170 Veterans Affairs hospital networks.
Orthocell will use its existing U.S. distributor network to reach military and veteran affairs surgeons in these hospital systems.
The recent clinical use of Remplir in 23 surgical procedures on injured soldiers in Ukraine, across both primary and secondary nerve repair applications, led to this expansion into the defence setting.
The firm noted that the Ukraine experience highlights key attributes of the device, including its portability, ease of use, and suitability for treating major traumatic injuries commonly encountered in military settings.
Commenting on this milestone, Orthocell Managing Director Paul Anderson said," Orthocell is well positioned to capitalise on this expanded access with its existing network of distributors and in-house sales and medical education teams".
Orthocell's portfolio of products includes collagen-based medical devices that facilitate tissue reconstruction and healing across a variety of dental and orthopaedic reconstructive applications.
OCC.AX has traded between A$0.70 and A$1.70 in the last year. The stock closed Thursday's trading at A$1.02, down 5.56%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.